Hendershot Investments Inc. Sells 14,065 Shares of Pfizer Inc. (NYSE:PFE)

Hendershot Investments Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 38.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,097 shares of the biopharmaceutical company’s stock after selling 14,065 shares during the quarter. Hendershot Investments Inc.’s holdings in Pfizer were worth $618,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in PFE. Olistico Wealth LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $29,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer during the second quarter valued at approximately $34,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $28.51 on Friday. The business’s fifty day simple moving average is $29.05 and its 200-day simple moving average is $28.04. The company has a market cap of $161.55 billion, a PE ratio of -475.09, a PEG ratio of 1.02 and a beta of 0.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $35.28.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the firm posted $0.67 earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.89%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.